Patients with HNSCC show abundant PD-1 expression in CD4+ T cells and CD8+ T cells, and both PD-L1 and PD-L2 react with PD-1 to mediate the signaling axis for immune suppression in the tumor microenvironment (TME). The gene discussed is PDCD1; the disease is neoplasm.